Greenwich Rx recalls glutathione injection over microbial contamination

Greenwich Rx initiated a recall of its Glutathione Injection product on October 1, 2026, according to an FDA enforcement report dated October 28, 2026. The recall was classified as Class I, with the recalling firm listed as Greenwich Rx and the reason for recall given as microbial contamination of sterile products.¹

The affected product is Glutathione Injection, combining Glutathione-L, Ascorbic Acid, Sodium Hydroxide, and Bacteriostatic Water, formulated at 200 mg/mL in a 10 mL multi-dose vial for subcutaneous use only, sold by prescription.¹ The recall covers 4,319 vials and was voluntary, initiated by the firm.¹

The affected lots span a range of codes beginning with Lot # 0060-062426-1, with a beyond-use date of 10/02/2026, through Lot # 0060-081826-1, with a beyond-use date of 11/26/2026.¹

The product was distributed nationwide in the United States, and the firm's initial notification method was a press release.¹ Greenwich Rx is based in Tomball, Texas, at 9733 Fm 2902 Rd., Suite 100.¹ The FDA's center classification date for this recall was October 27, 2026.¹ The recall's status was listed as ongoing as of the October 28, 2026 report date.¹